Overview
Coherus Q3 2025 sales miss analysts' expectations, adjusted net loss narrows less than expected
LOQTORZI net revenue rises 12% over Q2 2025, driven by higher patient demand
Company expands CHS-114 clinical program to include colorectal cancer
Outlook
Coherus expects multiple data readouts from ongoing studies throughout 2026
Company is expanding CHS-114 program to include colorectal cancer
Coherus plans to combine LOQTORZI with internal candidates for new indications
Result Drivers
LOQTORZI DEMAND - Higher patient demand and increased treatment duration drove a 12% increase in LOQTORZI net revenue over Q2 2025
NCCN GUIDELINES - Revised NCCN guidelines granting LOQTORZI preferred status drive demand growth
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Sales | Miss | $11.57 mln | $13.41 mln (5 Analysts) |
Q3 Adjusted Net Income | Miss | -$38.90 mln | -$33.54 mln (5 Analysts) |
Q3 Net Income | -$35.53 mln | ||
Q3 Operating Income | -$44.33 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Coherus Oncology Inc is $6.00, about 73.9% above its November 5 closing price of $1.57
Press Release: ID:nGNX5xJZLw
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)